UNITED STATES SECURITIES AND EXCHANGE COMMISSION July 18, 2008

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Amgen, Inc.

File No. 0-12477 - CF#21620

Amgen, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on February 28, 2008.

Based on representations by Amgen, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.63 through November 27, 2017

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Patti J. Dennis Chief, Office of Disclosure Support